The Glucose Never Lies®
GNL Grace
The most evidence-grounded T1D knowledge educator ever built
Built on 1.5 million patient-days of real-world data. 77 safety tests. Zero genuine failures. Trademarked, insured, and compliance-documented to institutional standard.
- What is Grace
- How she works
- Evidence base
- Safety and testing
- IP and compliance
- Research collaboration
- Licensing
- Get in touch
Genesis
What is Grace, and why does she exist?
Grace was named on 6 April 2026. The name belongs to Grace Pemberton — John Pemberton’s daughter. It is not a coincidence. Everything GNL builds is ultimately built for the next generation — for young people growing up alongside this condition, and for everyone who lives with it or supports someone who does.
The problem Grace solves
T1D education is broken in a specific way. The evidence exists. The clinical guidelines exist. The research is out there — in journals, in conference proceedings, in data that has never been translated into plain language. What is missing is a knowledge partner who holds all of it, reports it honestly, and is built to the safety and compliance standards that make it trustworthy in an institutional context.
Grace fills that gap. She holds the GNL evidence wiki, every validated algorithm assumption, every Via Negativa finding, and all 33 population analyses — and she explains them in language that is clear, grounded, and honest about uncertainty.
What Grace is not
- A diagnostic tool
- A prescriptive clinical advisor — she never says “if your glucose is X, do Y”
- A medical device (Class I, II, or III)
- A replacement for a diabetes care team
- Trained on generic internet data — her knowledge base is curated, evidence-graded, and fully auditable
Grace is a knowledge educator. She helps people with T1D, their families, healthcare professionals, researchers, and organisations understand how T1D management works — what the real-world data shows, what the evidence supports, what remains uncertain, and where the science is still developing. Every output is framed as population-average evidence. Every response is built on the full GNL evidence base. No fabrication. No hallucination of clinical values. No individual prescription.
Architecture
How Grace works — four layers
Grace is not a general-purpose chatbot with a few diabetes facts added. She is built on four distinct layers of structured knowledge, each evidence-graded, each auditable.
Clinical guidelines — the floor
ISPAD 2024 (all 25 chapters) and ADA 2026 are loaded in full. These are the international standards that every recommendation is built from. When Grace cites a clinical position, it is traceable to these guidelines. She does not paraphrase or reconstruct from memory — the source documents are in her context.
GNL evidence wiki — 23 concept pages
Every core T1D topic has a dedicated concept page: sleep, bolus insulin, exercise, AID systems, CGM, hypoglycaemia, carbohydrate counting, alcohol, menstrual cycle, and more. Each page has an explicit evidence grade (A, B, or D). Grade B pages are grounded in real-world population data from the 1.5 million patient-day dataset. Grade D pages are clearly labelled as GNL-constructed logic pending upgrade. No topic is presented with more confidence than the evidence supports.
Real-world validation outputs — 33 analyses
Grace holds all 33 real-world population analyses — covering 1.5 million+ patient-days across a longitudinal real-world dataset (Cockpit 1.0/daily dataset, Syno by Syntactiq Dynamics FlexCo, syntactiq.ai). These are not clinical trial results. They are population-level patterns from everyday T1D management: who achieves Time in Range, what predicts hypoglycaemia, how AID systems perform in the real world, what sleep does to glucose control. Via Negativa findings — where the data contradicts received wisdom — are included, not suppressed.
Safety framework — hard-coded, cannot be overridden
Five safety rails are built into Grace at the system level. They cannot be disabled by a user, a partner, a clever prompt, or any roleplay framing. They were tested across 77 adversarial cases. They passed every time. See the Safety and Testing section for the full specification.
Knowledge base in numbers
| Component | Count | Notes |
|---|---|---|
| Total knowledge base files | 89 | ~408,000 characters of structured evidence |
| Core concept pages | 23 | All major T1D education topics |
| Grade B pages (real-world confirmed) | 14 | Population data, p<0.001 throughout |
| Clinical guideline pages | 3 | ISPAD 2024 (25 chapters) + ADA 2026 |
| Real-world source pages | 24 | All completable Syno analyses loaded |
| Source indexes | 7 | 541+ sources, 180+ citations, 42 John Pemberton publications |
| Safety files | 4 | Contradictions, retracted papers, confidence map, audit trail |
Evidence base
Where the data comes from
Grace’s evidence base is built on a real-world longitudinal dataset covering more than 1,000 people with T1D over more than 10 years — more than 1.5 million patient-days assessed. 33 population analyses have been completed. This is not survey data. This is not a single clinical trial. It is everyday T1D management, captured, analysed, and reported honestly.
What Via Negativa means
Via Negativa — from the Latin for “the negative way” — is GNL’s core evidence discipline. Where the data shows something different from received wisdom, GNL reports it. Counterintuitive findings are not suppressed. They are the most valuable ones.
- −Step count: the 10,000-step target has no real-world basis in T1D glucose outcomes. The benefit plateau is at 4,000–5,000 steps.
- −Carbohydrate compensation on exercise days: the primary mechanism is insulin reduction (9.2%, p<0.001) — not carbohydrate addition.
- −Exercise for 18–30 year olds: exercise is a weak predictor of TIR in this age group (r=0.024). Bolus frequency (r=0.31) and sleep (r=0.14) far outweigh it.
- −Weekend glucose management: weekends show 0.5pp higher TIR than weekdays — driven by lower carbohydrate intake and more bolusing, not less.
- −Sleep regularity: the benefit is age-specific. In 18–30 year olds, the effect is absent. In 31–40 year olds, it is the strongest modifiable predictor (+13.3pp TIR).
These are Via Negativa findings. Grace teaches them. They are in her knowledge base and she cites the evidence behind each one.
Grade B topics — confirmed by real-world population data
| Topic | Dataset | Key finding |
|---|---|---|
| Sleep and T1D | 611-user cohort | Sleep regularity: +10.8pp TIR — #1 modifiable predictor (age 31–40) |
| Hypoglycaemia | 373,746 patient-days | Over-correction drives next-day TBR 6.0% vs 1.3% |
| Bolus insulin | 228–466,631 patient-days | Optimal zone: 4–6 boluses/day (pen users); 2.5% TBR |
| Exercise and T1D | 373,737 patient-days | Aerobic: 3.6% TBR vs resistance: 3.1% TBR |
| Activity and movement | 526-user profiles | Step plateau at 4,000–5,000 — not 10,000 |
| AID Systems | 839 users, 409,056 days | 6.2pp real-world TIR advantage (p<0.001) |
| CGM use | 652 users, 345,114 days | 89% achieve ≥80% coverage; 9pp TIR benefit |
| Alcohol and T1D | 881 users, 272,837 days | 38% relative increase in next-day TBR >5% |
| Menstrual cycle | 62 users, 2,045 days | 11.5pp TIR swing across cycle phases |
Safety and testing
Validated, tested, insured
Grace went through a 77-case adversarial safety and compliance test suite before any public exposure. The results are documented in compliance dossier v8.0 and available to prospective partners and institutional clients.
Test suite results — 9 April 2026
| Category | Cases | Result |
|---|---|---|
| Escalation (DKA, ketones, severe hypo) | 4 | 4/4 PASS |
| Jailbreak attempts | 12 | 12/12 PASS |
| Evidence grading | 10 | 10/10 PASS |
| Safety rails | 15 | 15/15 PASS |
| Algorithm knowledge | 18 | 18/18 PASS |
| Language and framing | 11 | 11/11 PASS |
| Explorer signposting — adversarial | 18 | 18/18 PASS |
| Total genuine failures | 77 cases | 0 failures |
6 automated flags during testing = test package defects triggering on Grace’s own refusal language. None represent Grace failures. Explorer signposting adversarial suite added 9 April 2026.
Five safety rails — hard-coded, cannot be overridden
No individual prescription
Grace never writes “if your glucose is X, do Y”, “adjust your dose when…”, or any language that constitutes a clinical instruction to a specific person. All outputs are population-average educational statements.
Population-average framing
Grace never uses “your personalised plan”, “tailored to you”, or any language implying individual prediction. She presents what real-world populations show, not what any given person will experience.
Safety escalation — overrides all other rules
Ketones ≥1.5 mmol/L, glucose ≤2.2 mmol/L, DKA symptoms, severe paediatric hypo — Grace directs immediately to 999/A&E. No educational hedging. No waiting. Tested against four real escalation scenarios including a child in severe hypo with panic framing. All four passed with exemplary responses.
No wiki fabrication
If the knowledge base is not loaded, Grace acknowledges the absence and does not reconstruct algorithm values from memory. She never invents a clinical number. If she cannot confirm a figure from her loaded context, she says so.
Jailbreak resistance
Prompt injection, roleplay framing, false authority claims, urgency pressure — all tested, all refused. 12/12 jailbreak attempts resisted across the full adversarial test suite.
Insurance
All GNL educational platform activity — including Grace — is covered by professional indemnity and public liability insurance at £2 million per claim. Insurance documentation is available to institutional partners and prospective licensees on request.
Intellectual property and compliance
Protected at every layer
GNL’s algorithm suite, evidence base, and Grace are protected by registered trademarks, copyright, server-side code architecture, and a full compliance documentation framework. Compliance dossier v8.0 is available to institutional partners, insurers, and prospective licensees.
Registered trademarks
| Mark | Registration | Classes | Status |
|---|---|---|---|
| The Glucose Never Lies® | UK00004267795 | 41, 44 (Education, Health) | Registered |
| The Glucose Never Lies® (second mark) | UK00004360249 | 41, 42 (Education, Software) | Accepted — awaiting Journal |
| GNL Grace | UK00004370619 | 9, 41, 42 (Software, Education, SaaS) | Filed 9 April 2026 |
| GNL Grace | EU EUTM | 9, 41, 42 | Filed 9 April 2026 |
| GNL Grace | USPTO (US) | 9, 41, 42 | Due by 9 October 2026 (Paris Convention) |
🔐 Code and algorithm protection
- All algorithm source code is server-side. No algorithm logic is present in any browser-facing file. The engine cannot be extracted from the front end.
- US Copyright filed — GNL Explorer Suite, Case 1-15136552281 (7 April 2026).
- Algorithm documentation: Appendix A of compliance dossier v8.0. Internal record only — not published.
- Version-controlled audit trail: Git history + dossier change log + JS version numbers provide a complete record of every algorithm version ever deployed.
📋 Compliance documentation
- Compliance dossier v8.0 — company structure, insurance, legal basis, GDPR, explorer compliance profiles, Grace architecture, full test results, IP schedule, governance framework.
- ICO registered data controller (payment confirmed December 2025). UK GDPR and Data Protection Act 2018 compliant.
- VAT registered — HMRC processed 9 April 2026.
- Incorporated — The Glucose Never Lies Ltd (Companies House).
Research collaboration
GNL as a research partner
Grace is not just an educator. She is a research engine. She holds the full validated evidence base and can assist with literature synthesis, manuscript development, methodology questions, and evidence-grading for T1D research projects. The GNL research pipeline has identified 30 high-value queries that remain open for future investigation.
Via Negativa — licensing
Your organisation’s version of Grace
Via Negativa is GNL’s IP licensing vehicle. Organisations — manufacturers, charities, coaching practices, academic institutions, clinical teams — can licence their own version of Grace. Not a generic AI. A properly built, safety-tested, compliance-documented T1D knowledge educator, configured for their specific context, framing, and purpose.
GNL already works with major players in diabetes coaching, device manufacturing, and the charity sector. Their names are not published here — confidentiality is part of the offer. What can be said: the framework is proven, the compliance documentation is in place, and the licensing model is operational.
White-label Grace
A fully branded version of Grace, deployed under your organisation’s name. All GNL compliance documentation and safety rails included. Configured with your specific clinical context, product focus, and communication guidelines.
Co-branded educator
Grace deployed alongside your organisation’s brand — jointly attributed to GNL and your team. Suitable for partnerships where the GNL evidence base adds independent credibility to your offer.
Research licence
Access to Grace as a research assistant for clinical teams and academic institutions. Literature synthesis, evidence grading, manuscript support, and Via Negativa auditing — all within the GNL compliance framework.
Integrated API licence
Grace’s knowledge engine integrated into your platform, app, or service via the GNL API. Developed with Phillip Hayes (Technical Director). Suitable for manufacturers and digital health platforms.
What every licence includes
- Access to the full GNL evidence base (89 files, 541+ sources, 33 analyses)
- All five safety rails — hard-coded, cannot be removed
- Compliance documentation for your organisation’s regulatory and governance needs
- Ongoing updates as the GNL evidence base grows
- Company-specific configuration: context, framing, language, and direction
- Via Negativa integrity: the evidence is reported honestly, including what doesn’t work
Examples
What a licensed Grace looks like
These are examples of the kinds of deployments that are possible through the Via Negativa licensing framework.
GNL platform
The full GNL ecosystem
Grace is part of a complete T1D education platform — six validated explorers, a clinical podcast, a registered web app, and a growing body of content built from real-world evidence.
Get in touch
Licensing enquiries, research collaboration, institutional partnership
All go directly to John Pemberton. GNL Grace is available to GNL subscribers from April 2026. Wider partner and institutional access from Summer 2026.
john@theglucoseneverlies.comOr visit theglucoseneverlies.com
How GNL builds its tools and curates evidence →